HIGHLIGHTS
- who: Albert Grinshpun from the School have published the article: The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer, in the Journal: (JOURNAL) of 25/08/2022
- how: More data from these studies will shed light on the potential differential efficacy of the CDK4/6i their optimal sequencing and might assist in enhanced future decision-making for the many patients with ER+/HER2- MBC.
SUMMARY
Similarly, for patients treated with ribociclib and fulvestrant as their first-line treatment in the MONALEESA . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.